A new collaboration between Apertura and the National Institutes of Health (NIH) aims to advance a potential gene therapy for Niemann-Pick Disease Type C1 (NPC1), a rare and often fatal neurodegenerative disorder. Under a newly signed Cooperative Research and Development Agreement (CRADA), NIH and

NIH is seeking feedback from stakeholders to assist in defining specific, measurable indicators and incentives that reflect the collaborative, rigorous, and mission-driven nature of modern biomedical science. NIH is particularly interested in comments that include specific examples of measurable

There is an unmet need for safe, effective, long-term therapies for autoimmune disorders. NIH inventors have isolated a population of mammalian cells comprising about 75% or higher B-1a regulatory cells (Bregs) and methods of preparation of such cell populations as a therapeutic for immune-related